Hannah Blake interviews Doctor A
Here is the first of five anonymous interviews with healthcare professionals from a range of different demographics, to find out how they typically engage with pharma.
To coincide with our medical communications focus month, pharmaphorum speaks with five healthcare professionals to find out how they typically engage with pharma and their thoughts on how this could be improved in the future.
Throughout this series, we are looking to learn:
• How doctors typically engage with pharma companies?
• What a good interaction with pharma is like?
• What common characteristics define the pharma representatives with whom doctors typically have good interactions with?
• Would doctors value details and data from pharma around late stage trials activity and the new drugs pipeline?
• If yes, how would they like to receive this information, and through what channels?
• From a trust perspective, do doctors believe that pharma companies supply information in a transparent way?
• Other than drug information, what else is or could be provided by pharma companies to support a doctor’s work or create better interactions?
• What one thing could pharma companies provide doctors with through engagement that would be most useful in the future?
• Do modern technologies, such as tele-reach detailing and use of iPads, add value to doctor’s knowledge and interaction with pharma?